Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)

被引：0
|
作者：
Fonseca, Vivian
Dejager, Sylvie
Albrecht, Diego
Shirt, Lynda
Schweizer, Anja
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [1] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
  • [2] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [3] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
  • [4] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES, 2013, 62 : A282 - A282
  • [5] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A273 - A273
  • [6] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A291 - A291
  • [7] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [8] Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes (T2DM): Superior efficacy and tolerability with vildagliptin
    Iwamoto, Yasuhiko
    Kashiwagi, Atsunori
    Yamada, Nobuhiro
    Terao, Shinji
    Suzuki, Manabu
    [J]. DIABETES, 2008, 57 : A167 - A167
  • [9] Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus (T2DM) as add-on to insulin glargine
    Menge, B. A.
    Kapitza, C.
    Hincelin-Mery, A.
    Roy-Duval, C.
    Delfolie, A.
    Coester, H. -V.
    Forst, T.
    Meier, J. J.
    [J]. DIABETOLOGIA, 2014, 57 : S38 - S38
  • [10] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A70 - A70
12345